Drug Repurposing in Chagas Disease: Chloroquine Potentiates Benznidazole Activity against Trypanosoma cruzi <i>In Vitro</i> and <i>In Vivo</i>-Reference-Cited by-同舟云学术

Drug Repurposing in Chagas Disease: Chloroquine Potentiates Benznidazole Activity against Trypanosoma cruzi In Vitro and In Vivo

Published:2022-11-15 Issue:11 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Pandey Ramendra P.¹²,Nascimento Marilda Savoia²³,Franco Caio Haddad⁴,Bortoluci Karina⁵,Silva Marcelo Nunes⁶,Zingales Bianca⁶,Gibaldi Daniel⁷,Castaño Barrios Leda⁷,Lannes-Vieira Joseli⁷,Cariste Leonardo Moro⁸,Vasconcelos Jose Ronnie⁸⁹^ORCID,Moraes Carolina Borsoi⁴,Freitas-Junior Lucio H.⁴,Kalil Jorge¹²,Alcântara Laura¹²³,Cunha-Neto Edecio¹²

Affiliation:

1. Laboratory of Immunology, Heart Institute, School of Medicine, University of São Paulo, São Paulo, Brazil

2. School of Medicine, University of São Paulo, São Paulo, Brazil

3. Institute of Tropical Medicine of São Paulo, São Paulo, Brazil

4. Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil

5. Department of Pharmacology, Federal University of São Paulo, São Paulo, Brazil

6. Department of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil

7. Institute Oswaldo Cruz—Fiocruz, Rio de Janeiro, Brazil

8. Recombinant Vaccines Laboratory, Department of Biosciences, Federal University of São Paulo, São Paulo, Brazil

9. Department of Microbiology, Immunology, and Parasitology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil

Abstract

Drug combinations and drug repurposing have emerged as promising strategies to develop novel treatments for infectious diseases, including Chagas disease. In this study, we aimed to investigate whether the repurposed drugs chloroquine (CQ) and colchicine (COL), known to inhibit Trypanosoma cruzi infection in host cells, could boost the anti- T. cruzi effect of the trypanocidal drug benznidazole (BZN), increasing its therapeutic efficacy while reducing the dose needed to eradicate the parasite. The combination of BZN and COL exhibited cytotoxicity to infected cells and low antiparasitic activity.

Funder

Fundação de Amparo à Pesquisa do Estado de São Paulo

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00284-22

Reference63 articles.

1. World Health Organization. 2022. Chagas disease (also known as American trypanosomiasis). World Health Organization Geneva Switzerland. https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis).

2. Global economic burden of Chagas disease: a computational simulation model

3. Drug discovery for chagas disease: A viewpoint

4. Chagas Disease: From Discovery to a Worldwide Health Problem

5. Comparação do desfecho entre a cardiopatia chagásica e a miocardiopatia dilatada idiopática

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities;Journal of Pharmaceutical Analysis;2024-08

2. Synthesis and Anti-Trypanosoma cruzi Activity of New Pyrazole-Thiadiazole Scaffolds;Molecules;2024-07-27

3. Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status;Expert Opinion on Investigational Drugs;2024-05-14

4. New drug discovery strategies for the treatment of benznidazole-resistance in Trypanosoma cruzi , the causative agent of Chagas disease;Expert Opinion on Drug Discovery;2024-05-07

5. Global Health Priority Box: Discovering Flucofuron as a Promising Antikinetoplastid Compound;Pharmaceuticals;2024-04-25